| Molecular formula | C225H360N76O67S |
|---|
| Molecular weight | 5234 g/mol |
|---|
| Registered trials | 371 |
|---|
| PubChem CID | 16132356 |
|---|
Regulatory Status
Somatropin recombinant is discussed here as a research compound, and this monograph does not draw on an approved product label. No FDA label data were available for this entry, so approved-use claims are not made.
What Somatropin Recombinant Is
Somatropin recombinant is a large recombinant protein compound, identified in chemical databases under PubChem CID 16132356. It has a molecular formula of C225H360N76O67S and a molecular weight near 5,234 daltons, consistent with a peptide hormone structure rather than a small molecule. No approved labeling accompanies this entry, so mechanism and indication details are not summarized here.
Trial Footprint
Registries list 371 total trials associated with this compound, spanning a range of study designs and patient populations. Among the sampled studies, one long-term trial examined use in short children born small for gestational age and has completed. Another sampled study looked at growth hormone and insulin-like growth factor status in relation to growth failure in ataxia telangiectasia, though its status is listed as unknown. A separate completed study examined growth hormone treatment in patients with aggrecan deficiency. These examples illustrate the range of populations studied rather than any established outcome.
FAQ
This monograph treats somatropin recombinant as a research compound without reference to an approved label. No indication or benefit claims are made here, since no approved labeling data were available for this entry.
It is a large recombinant protein with the molecular formula C225H360N76O67S and a molecular weight of roughly 5,234 daltons. It is catalogued in PubChem under CID 16132356.
Public registries list 371 trials associated with this compound. Sampled studies cover diverse populations, including short children born small for gestational age and patients with aggrecan deficiency.
No adverse event report data were available for this entry, so no side effect summary is included here.
Sampled trials include a completed long-term study in small-for-gestational-age children, a study of growth hormone status in ataxia telangiectasia with unknown current status, and a completed study in aggrecan deficiency. These examples show the range of research interest rather than confirmed outcomes.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem ClinicalTrials.gov
Updated 2026-08-04